Description
Elagolix sodium is a human GnRH (Gonadotropin-Releasing Hormone) receptor antagonist with an IC₅₀ and Ki of 0.25 and 3.7 nM, respectively. Elagolix alters the level of pituitary GnRH suppression and, as a result, titrating circulating estrogen levels.
Elagolix sodium is a human GnRH (Gonadotropin-Releasing Hormone) receptor antagonist with an IC₅₀ and Ki of 0.25 and 3.7 nM, respectively. Elagolix alters the level of pituitary GnRH suppression and, as a result, titrating circulating estrogen levels.
B2112 | Elagolix sodium DataSheet
Alternate Name/Synonyms: Sodium (R)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethyl)amino)butanoate; NBI56418
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 832720-36-2
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₃₂H₂₉F₅N₃NaO₅
Molecular Weight: 653.57
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A human GnRH (Gonadotropin-Releasing Hormone) receptor antagonist
MDL Number: N/A
PubChem CID: 24785956
SMILES: CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)CC(C3=CC=CC=C3)NCCCC(=O)[O-])C4=C(C(=CC=C4)OC)F.[Na+]
InChi: InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1
InChi Key: DQYGXRQUFSRDCH-UQIIZPHYSA-M
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |